## <u>REMARKS</u>

The Examiner has required an election under 35 U.S.C. § 121 and § 372 of one of the following groups:

Group I:

Claims 42-66, drawn to a method of identifying a compound that

modulates fungal tRNA splicing endonuclease activity; and

Group II:

Claims 67-82, drawn to a method for treating, preventing managing, or

ameliorating a fungal infection by administering a compound to a subject.

In response, Applicant hereby elects to prosecute the claims of Group I, drawn to a method of identifying a compound that modulates fungal tRNA splicing endonuclease activity.

The Examiner has also required species elections under 35 U.S.C. § 121. In particular, upon election of the claims of Group I, the Examiner has required that Applicant elect a single species from each of the following:

- A. A single specific selection of a type of a compound that either "reduces" or "increases" fungal tRNA splicing endonuclease activity.
- B. A single specific assaying method of using either intact "cells" or "cell-free extract".
- C. A single specific selection of a specific assay method of either using a reporter gene assay or using FRET analysis.

In response, Applicant hereby elects the following:

- A. A compound that reduces fungal tRNA splicing endonuclease activity.
- B. An assay that uses intact cells.
- C. A reporter gene assay.

Applicant believes that claims 42, 43, 45, 46, 48, 62, 63, and 64 read on the elected species.

Applicant respectfully requests entry of the amendments and remarks made herein into the file history of the present application.

Respectfully submitted,

Date:

December 23, 2008

Reg. No.)

**Jones Day** 

222 East 41<sup>st</sup> Street

New York, New York 10017-6702

(212) 326-3939

: Jamper J. Chreda Reg No. 46,617

NYI-4148107v12